P. Koralewski
Impact in
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Cancer Immunotherapy and Biomarkers
- Otorhinolaryngology top 0.5%
Papers in
- Oncology 14
- Colorectal Cancer Treatments and Studies 6
- Cancer Immunotherapy and Biomarkers 5
- CAR-T cell therapy research 3
- Cancer Treatment and Pharmacology 2
-
- Head and Neck Cancer Studies 4
- Co-authors
- Carsten Bokemeyer (4 shared papers)Filippo Guglielmo Maria de Braud (2 shared papers)Gunter Schuch (2 shared papers)Angela Zubel (2 shared papers)Igor Bondarenko (2 shared papers)Cezary A. Szczylik (5 shared papers)Alain Ravaud (4 shared papers)Bernard J. Escudier (4 shared papers)
- Journals
- Annals of Oncology (10 papers)Journal of Clinical Oncology (8 papers)The Lancet Oncology (2 papers)Journal of Thoracic Oncology (1 paper)European Urology (1 paper)
- Partner nations
- PolandUnited StatesFrance
In The Last Decade
P. Koralewski
34 papers receiving 8.2k citations
P. Koralewski's Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 4.5k
- Otorhinolaryngology 566
- Cancer Research 1.4k
- Pulmonary and Respiratory Medicine 2.9k
- Hepatology 481
Countries citing papers authored by P. Koralewski
This map shows the geographic impact of P. Koralewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Koralewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Koralewski more than expected).
Fields of papers citing papers by P. Koralewski
This network shows the impact of papers produced by P. Koralewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Koralewski. The network helps show where P. Koralewski may publish in the future.
Co-authors
The 25 scholars most cited alongside P. Koralewski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1845 |
| 2 | Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1355 |
| 3 | Capecitabine as Adjuvant Treatment for Stage III Colon Cancer Hit paper breakdown → | 2005 | 990 |
| 4 | Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy Hit paper breakdown → | 2007 | 844 |
| 5 | Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study Hit paper breakdown → | 2000 | 686 |
| 6 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Hit paper breakdown → | 2011 | 665 |
| 7 | The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial Hit paper breakdown → | 2010 | 446 |
| 8 | 2003 | 233 | |
| 9 | 2011 | 231 | |
| 10 | 2008 | 156 | |
| 11 | 2006 | 136 | |
| 12 | Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2024 | 134 |
| 13 | Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 Hit paper breakdown → | 2022 | 120 |
| 14 | 2012 | 97 | |
| 15 | 2010 | 86 | |
| 16 | 2008 | 82 | |
| 17 | 2008 | 51 | |
| 18 | 2008 | 51 | |
| 19 | 2013 | 51 | |
| 20 | 2001 | 45 |
About P. Koralewski
P. Koralewski is a scholar working on Oncology, Otorhinolaryngology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Immunology, having authored 37 papers that have together received 8.5k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Head and Neck Cancer Studies (4 papers), CAR-T cell therapy research (3 papers), Immunotherapy and Immune Responses (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Oncology (4.5k citations), Otorhinolaryngology (566 citations), Cancer Research (1.4k citations), Pulmonary and Respiratory Medicine (2.9k citations) and Hepatology (481 citations). P. Koralewski has collaborated with scholars based in Poland, United States and France. Frequent co-authors include Carsten Bokemeyer, Filippo Guglielmo Maria de Braud, Gunter Schuch, Angela Zubel, Igor Bondarenko, Cezary A. Szczylik, Alain Ravaud, Bernard J. Escudier, Anna Pluzanska and Christine Chevreau. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, The Lancet Oncology, Journal of Thoracic Oncology and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.